Amoéba launches €6M placement in bid for its last market raise
What's the deal? Amoéba, a French industrial greentech developing natural microbiological solutions based on the patented use of amoebae, has launched a two-phase capital increase targeting roughly €6 million through a private placement. The company already holds subscription commitments totaling €3.9 million.
How it works: The private placement runs via an accelerated bookbuilding process at €0.416 per share — a 19.83% discount to the volume-weighted average price over the five trading sessions to September 23, 2026. It is set to close before market opening on September 25.
Why now? The two-part raise, which could generate gross proceeds of more than €15 million, is intended to cover the company's financing needs over the next 12 months. Amoéba describes it as its final market financing before achieving financial self-sufficiency.
A second tranche, open to all investors with preferential subscription rights, targets around €9.6 million through shares with attached warrants. That subscription period runs from October 8 to October 23, 2026, at the same €0.416 price.
What's the endgame? Amoéba expects the planned monetization of its Willa cosmetics asset in 2027 to provide additional resources until it reaches self-sufficiency. The company is targeting revenue of about €40 million and a current operating margin above 10% by 2030, then aims to double revenue to €80 million by 2032.
What could go wrong? If the private placement is completed at €6 million, dilution for non-participating shareholders would reach 18.53%. As of the announcement, four qualified investors had committed to the round.
The signal: The offering is small by market standards, sitting in the bottom quartile for round size. But its framing as a bridge to profitability — backed by a specific asset sale and 2030 revenue targets — signals a listed greentech trying to draw a line under its reliance on public markets.
Read more: actusnews.com
Image credit: USDA Forest Service
